[go: up one dir, main page]

ES2192866T3 - Polvo seco para inhalacion. - Google Patents

Polvo seco para inhalacion.

Info

Publication number
ES2192866T3
ES2192866T3 ES99952212T ES99952212T ES2192866T3 ES 2192866 T3 ES2192866 T3 ES 2192866T3 ES 99952212 T ES99952212 T ES 99952212T ES 99952212 T ES99952212 T ES 99952212T ES 2192866 T3 ES2192866 T3 ES 2192866T3
Authority
ES
Spain
Prior art keywords
inhalation
dry powder
inhalable
particle size
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99952212T
Other languages
English (en)
Inventor
Manfred Keller
Rudi Muller-Walz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jago Research AG
Original Assignee
Jago Research AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4230229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2192866(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jago Research AG filed Critical Jago Research AG
Application granted granted Critical
Publication of ES2192866T3 publication Critical patent/ES2192866T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Uso de estearato magnésico en formulaciones de polvo seco para inhalación, que comprende un soporte farmacéuticamente no activo en un tamaño de partícula no inhalable y un principio activo farmacéutico finamente dividido en un tamaño de partícula inhalable, con el objeto de mejorar la resistencia a la humedad.
ES99952212T 1998-11-13 1999-11-10 Polvo seco para inhalacion. Expired - Lifetime ES2192866T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH228698 1998-11-13

Publications (1)

Publication Number Publication Date
ES2192866T3 true ES2192866T3 (es) 2003-10-16

Family

ID=4230229

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02025796T Expired - Lifetime ES2298323T3 (es) 1998-11-13 1999-11-10 Inhalador de polvo seco multidosis con reserva de polvo.
ES99952212T Expired - Lifetime ES2192866T3 (es) 1998-11-13 1999-11-10 Polvo seco para inhalacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02025796T Expired - Lifetime ES2298323T3 (es) 1998-11-13 1999-11-10 Inhalador de polvo seco multidosis con reserva de polvo.

Country Status (22)

Country Link
US (2) US6645466B1 (es)
EP (4) EP1131059B1 (es)
JP (4) JP2002529498A (es)
CN (1) CN1150895C (es)
AT (2) ATE233550T1 (es)
AU (1) AU756852B2 (es)
CA (1) CA2347856C (es)
CY (1) CY1107350T1 (es)
CZ (1) CZ303154B6 (es)
DE (2) DE59914603D1 (es)
DK (2) DK1131059T3 (es)
ES (2) ES2298323T3 (es)
HU (1) HU226164B1 (es)
NO (1) NO20012346L (es)
NZ (1) NZ511527A (es)
PL (1) PL200941B1 (es)
PT (2) PT1131059E (es)
RO (1) RO122660B1 (es)
RU (1) RU2221552C2 (es)
SK (1) SK284889B6 (es)
WO (1) WO2000028979A1 (es)
ZA (1) ZA200103627B (es)

Families Citing this family (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
EP1158958B1 (en) * 1999-03-05 2007-06-06 CHIESI FARMACEUTICI S.p.A. Improved powdery pharmaceutical compositions for inhalation
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
ITMI991582A1 (it) * 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
DE19947235A1 (de) 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
AU7685200A (en) * 1999-10-12 2001-04-23 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
ATE364381T1 (de) * 2000-04-17 2007-07-15 Vectura Ltd Formulierungen zur verwendung in inhalationsvorrichtungen
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
BR0015884A (pt) * 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
DK1296651T3 (da) * 2000-06-27 2008-02-11 Vectura Ltd Fremgangsmåde til fremstilling af partikler til anvendelse i et farmaceutisk præparat
EP1296651B2 (en) 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
BR0107304A (pt) 2000-10-12 2002-08-13 Boehringer Ingelheim Pharma Pó para inalação contendo tiotrópio
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DK2283818T3 (en) † 2000-11-30 2017-10-16 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
DK1337240T4 (en) 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
EP1337239B2 (en) * 2000-11-30 2015-11-25 Vectura Limited Particles for use in a pharmaceutical composition
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
WO2003026631A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
DE10126924A1 (de) * 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
ATE267591T1 (de) * 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
WO2003013633A1 (en) * 2001-08-09 2003-02-20 Glaxo Group Limited Inhalation device with a pharmaceutical composition
WO2003024396A2 (en) * 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
KR100947409B1 (ko) * 2002-03-01 2010-03-12 키에시 파르마슈티시 엣스. 피. 에이. 포모테롤 초미세 조성물
DE10212264A1 (de) * 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
BR0308984A (pt) * 2002-04-04 2005-02-09 Boehringer Ingelheim Pharma Formulações em pó adequadas para inalação
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
UA80123C2 (en) 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
GB0208608D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
AU2003269889B2 (en) * 2002-06-17 2007-04-19 Epigenesis Pharmaceuticals, Llc Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US7087631B2 (en) 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US7078423B2 (en) 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
JP2006516531A (ja) * 2002-08-21 2006-07-06 ノートン　ヘルスケアー　リミテッド 吸入組成物
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
NZ538965A (en) * 2002-08-21 2006-11-30 Norton Healthcare Ltd Dry powder inhalation compositions
GB0219513D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions including coarse carrier
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
EP2319585A1 (en) 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, fluticasone and ipratropium or tiotropium
SE0203376D0 (sv) * 2002-11-15 2002-11-15 Astrazeneca Ab New process
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
PT1572622E (pt) * 2002-12-10 2006-08-31 Sepracor Inc Sal de levalbuterol
WO2004052374A1 (en) 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
CN102688224A (zh) * 2003-04-14 2012-09-26 维克特拉有限公司 用于提高剂量效率的药物组合物和装置
DE10317461A1 (de) * 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung
EP1625336B9 (en) 2003-05-21 2012-03-21 Alexza Pharmaceuticals, Inc. Use of a layer of solid fuel, method for producing such a layer and associated heating unit
EP1635844A1 (en) * 2003-05-22 2006-03-22 ALTANA Pharma AG Salmeterol and ciclesonide combination
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1646370A1 (en) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
WO2005004845A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
GB0316341D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
US20060210485A1 (en) * 2003-07-11 2006-09-21 Marian Thomas Pharmaceutical formulations
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
PL1670482T5 (pl) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
WO2005044187A2 (en) * 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
EP1684767A1 (en) 2003-11-03 2006-08-02 Norton Healthcare Limited Soft steroid compositions for use in dry powder inhalers
DE10352277A1 (de) * 2003-11-08 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
CA2547782A1 (en) * 2003-12-03 2005-06-16 Microdrug Ag Medical product containing tiotropium
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
SE0303569L (sv) * 2003-12-03 2005-06-04 Microdrug Ag DPI för avlämning av fuktkänsliga medikament
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
EP1699436A2 (en) * 2003-12-12 2006-09-13 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
WO2005074982A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
PT1713473E (pt) * 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
DE602005007708D1 (de) * 2004-02-06 2008-08-07 Meda Pharma Gmbh & Co Kg Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1720577A2 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Ciclesonide and glycopyrronium combination
WO2005092333A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
JP2007530563A (ja) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド （ｓ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
EP1740188A1 (en) * 2004-04-20 2007-01-10 Altana Pharma AG Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
ES2909080T3 (es) 2004-04-23 2022-05-05 Cydex Pharmaceuticals Inc Formulación de DPI que contiene sulfoalquil éter ciclodextrina
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
SE530006C2 (sv) * 2004-06-18 2008-02-05 Mederio Ag Inhalator som använder balja
WO2006007213A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
AU2004322756B2 (en) 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
CA2579007A1 (en) * 2004-09-10 2006-03-16 Altana Pharma Ag Ciclesonide and syk inhibitor combination and methods of use thereof
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
DE102005029385B4 (de) * 2005-06-23 2018-12-27 Beiersdorf Ag Wirkstoffkombinationen aus Glycopyrroniumbromid und Chitosan
JP3955868B2 (ja) * 2004-12-27 2007-08-08 株式会社キングジム 書類等の綴じ具
WO2006069998A2 (de) 2004-12-27 2006-07-06 Beiersdorf Ag Glycopyrrolat in kosmetischen zubereitungen
WO2006094924A2 (en) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
ES2570332T3 (es) * 2005-03-16 2016-05-17 Meda Pharma Gmbh & Co Kg La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
EP2484382A1 (en) * 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
WO2006114379A1 (de) * 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
AU2012200449B2 (en) * 2005-12-21 2013-07-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
NZ568349A (en) 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
EP1976522B2 (en) * 2005-12-30 2019-07-03 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition containing montelukast
EP1803457A1 (en) * 2005-12-30 2007-07-04 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition containing montelukast
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
GB0606124D0 (en) 2006-03-28 2006-05-03 Reckitt Benckiser Healthcare Buprenorphine derivatives and uses thereof
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
DK2046787T3 (da) 2006-08-01 2011-07-18 Glaxo Group Ltd Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
RU2338552C2 (ru) * 2006-09-19 2008-11-20 Владимир Евгеньевич Небольсин Фармацевтическая композиция для ингаляции
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
AU2009276498A1 (en) * 2008-07-30 2010-02-04 Stc.Unm Formulations containing large-size carrier particles for dry powder inhalation aerosols
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
WO2010060875A1 (de) * 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Neue pulverförmige kristalline arzneimittel zur inhalation
EP2201977A1 (de) 2008-12-23 2010-06-30 Siegfried Generics International AG Dosiervorrichtung zur Erzeugung eines Gasstromes mit einem in diesem fein verteilten Wirkstoff
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) * 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
US20120082626A1 (en) * 2009-06-16 2012-04-05 Wen Tan Use of r-bambuterol as inhaled medicament and combination therapies for treatment of respiratory disorders
AU2009100698B4 (en) * 2009-07-17 2010-04-15 Astrazeneca Ab Combination
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
WO2011057235A2 (en) * 2009-11-09 2011-05-12 Virginia Commonwealth University Improved delivery of submicrometer and nonometer aerosols to the lungs using hygroscopic excipients or dual stream nasal delivery
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
ES2467928T3 (es) * 2009-12-23 2014-06-13 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR201000679A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Farmasötik bir kombinasyon içeren kuru toz formülasyonları.
BR112012024059B1 (pt) * 2010-04-01 2021-06-01 Chiesi Farmaceutici S.P.A. Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco
KR20130062268A (ko) * 2010-04-21 2013-06-12 키에시 파르마슈티시 엣스. 피. 에이. 정전하가 감소된 입자를 제공하는 방법
EP2611416B1 (en) 2010-09-03 2015-08-19 Pharmaterials Ltd. Pharmaceutical composition suitable for use in a dry powder inhaler
CA2813096C (en) * 2010-09-30 2019-10-29 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
SG11201401360XA (en) 2011-10-25 2014-05-29 Onclave Therapeutics Ltd Antibody formulations and methods
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
FI3412277T3 (fi) 2012-01-25 2023-03-23 Chiesi Farm Spa Kortikosteroidia ja beeta-adrenergista ainetta käsittävä kuivajauheformulaatio annettavaksi inhalaatiolla
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
KR20140131971A (ko) 2012-03-13 2014-11-14 레스피버트 리미티드 신규 약학 제제
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
RU2494730C1 (ru) * 2012-03-27 2013-10-10 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения болезней органов дыхания, содержащий в качестве активных веществ микронизированный салметерол ксинофоат и микронизированный флутиказона пропионат и способ его получения
ES2814336T3 (es) 2012-04-13 2021-03-26 Glaxosmithkline Ip Dev Ltd Partículas de agregado
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007767A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose and a ternary component
WO2014007766A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
EP2821062A1 (en) * 2013-07-01 2015-01-07 Arven Ilac Sanayi Ve Ticaret A.S. Novel dry powder inhaler formulations
PT3019153T (pt) * 2013-07-11 2018-12-04 Chiesi Farm Spa Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação
EP3060205A4 (en) * 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法
GB201321712D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
CN105828819A (zh) * 2014-04-08 2016-08-03 桑萨（巴巴多斯）公司 烟碱制剂及其制备方法
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
TR201818680T4 (tr) * 2014-07-09 2019-01-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi İnhalasyona yönelik formülasyonların hazırlanması için bir proses.
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
EP3244952A4 (en) 2015-01-14 2018-11-14 Respira Therapeutics, Inc. Powder dispersion methods and devices
WO2017077488A1 (en) * 2015-11-04 2017-05-11 Glenmark Pharmaceuticals Limited An inhalable fixed dose powder composition comprising glycopyrronium and formoterol
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
TWI745396B (zh) * 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
CN116889562A (zh) 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
KR20220155609A (ko) * 2017-05-11 2022-11-23 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
CN108175764B (zh) * 2017-12-19 2020-02-21 亿腾医药（苏州）有限公司 一种无水二丙酸倍氯米松无菌粉末及其吸入混悬液的制备方法
EP3746138B1 (en) 2018-02-02 2025-12-10 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
AU2019397436A1 (en) 2018-12-10 2021-07-22 The General Hospital Corporation Cromolyn esters and uses thereof
EP3673895A1 (en) * 2018-12-28 2020-07-01 Université Libre de Bruxelles Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
CN113476428B (zh) * 2021-01-28 2022-03-29 朗天药业(湖北)有限公司 一种吸入用硫酸沙丁胺醇溶液及其制备方法
GR1010358B (el) * 2021-09-14 2022-12-16 Elpen Ανωνυμος Εταιρεια Φαρμακευτικη Βιομηχανια, Σταθερο φαρμακευτικο σκευασμα που περιεχει βρωμιουχο τιοτροπιο, για χορηγηση απο το αναπνευστικο
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
EP4452223A1 (en) 2021-12-21 2024-10-30 Chiesi Farmaceutici S.p.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE98022C (es)
DD98022A1 (es) * 1972-06-30 1973-06-12
JPS5467023A (en) * 1977-11-07 1979-05-30 Banyu Pharmaceut Co Ltd Stabilization of medicine
IT7920688U1 (it) * 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB8622090D0 (en) * 1986-09-12 1986-10-22 Wellcome Found Pharmacologically active compounds
FR2651678B1 (fr) 1989-09-08 1992-04-30 Glaxo Group Ltd Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1995015151A1 (en) 1993-12-02 1995-06-08 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
JP2836493B2 (ja) * 1994-08-04 1998-12-14 田辺製薬株式会社 苦味隠蔽されたマレイン酸トリメブチン含有製剤
JPH08143476A (ja) * 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
JPH09216818A (ja) * 1995-12-04 1997-08-19 Kyowa Hakko Kogyo Co Ltd 硬カプセル剤
US6182655B1 (en) 1995-12-07 2001-02-06 Jago Research Ag Inhaler for multiple dosed administration of a pharmacological dry powder
EP1014943B1 (de) * 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
EP1158958B1 (en) 1999-03-05 2007-06-06 CHIESI FARMACEUTICI S.p.A. Improved powdery pharmaceutical compositions for inhalation

Also Published As

Publication number Publication date
NO20012346L (no) 2001-06-26
HUP0104226A2 (hu) 2002-02-28
WO2000028979A1 (de) 2000-05-25
JP2015061866A (ja) 2015-04-02
CN1150895C (zh) 2004-05-26
PL347640A1 (en) 2002-04-22
JP2002529498A (ja) 2002-09-10
EP2266548B1 (de) 2020-05-20
HU226164B1 (en) 2008-05-28
DE59914603D1 (de) 2008-02-14
RO122660B1 (ro) 2009-11-30
AU6457899A (en) 2000-06-05
CZ20011553A3 (cs) 2001-09-12
ATE233550T1 (de) 2003-03-15
PT1131059E (pt) 2003-07-31
CA2347856C (en) 2009-02-17
EP2266548A3 (de) 2012-12-26
HUP0104226A3 (en) 2003-12-29
EP1283036A1 (de) 2003-02-12
ATE382386T1 (de) 2008-01-15
SK284889B6 (sk) 2006-02-02
EP1862164A3 (de) 2012-12-26
EP2266548A2 (de) 2010-12-29
JP2011231124A (ja) 2011-11-17
US6645466B1 (en) 2003-11-11
RU2221552C2 (ru) 2004-01-20
SK6322001A3 (en) 2002-01-07
EP1283036B2 (de) 2020-01-01
CA2347856A1 (en) 2000-05-25
EP1862164A2 (de) 2007-12-05
NZ511527A (en) 2002-10-25
CN1326341A (zh) 2001-12-12
AU756852B2 (en) 2003-01-23
JP2016147899A (ja) 2016-08-18
DE59904488D1 (de) 2003-04-10
US20040202616A1 (en) 2004-10-14
PL200941B1 (pl) 2009-02-27
CZ303154B6 (cs) 2012-05-09
CY1107350T1 (el) 2012-12-19
US7186401B2 (en) 2007-03-06
PT1283036E (pt) 2008-03-06
EP1283036B1 (de) 2008-01-02
ES2298323T3 (es) 2008-05-16
DK1131059T3 (da) 2003-06-30
DK1283036T3 (da) 2008-03-25
NO20012346D0 (no) 2001-05-11
EP1131059B1 (de) 2003-03-05
EP1131059A1 (de) 2001-09-12
ZA200103627B (en) 2001-05-09

Similar Documents

Publication Publication Date Title
ES2192866T3 (es) Polvo seco para inhalacion.
BR0107869A (pt) Composições farmacêuticas eletrogiradas
AU2003274681A8 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
BRPI0309544B8 (pt) preparação farmacêutica oral estável ao armazenamento compreendendo oxicodona e naloxona
EE03805B1 (et) Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks
HUP1300117A2 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard pellets
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
ATE253896T1 (de) Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
DE69233130D1 (de) Kaubare zusammensetzung zur arzneimittelfreisetzung
LT2000064A (en) Flash-melt oral dosage formulation
TW355683B (en) Composition containing micronized nebivolol
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
JO2506B1 (en) Dosage titration device in hydrofluoroalkan propellants
BR0112847A (pt) Uso de uma forma de dosagem sólida
NO995127D0 (no) Stabiliserte tibolonblandinger
DE69907717D1 (de) Pharmazeutische formulierung in form eines trockenen pulvers
NO20051463L (no) Inhaleringssammensetninger med hoy legemiddelandel
DOP2001000130A (es) Sistema de administración oral controlada para la ingestión diaria de ciprofloxacina
ATE374600T1 (de) Pharmazeutische formulierung enthaltend olanzapin
PL348202A1 (en) Pharmaceutically active composition and dispensing device
TW200507884A (en) Stable topiramate formulations
EP1748774A4 (en) COMPOSITIONS CONTAINING FLAVONOIDS AND TOCOTRIENOLS AND RELATED METHODS